v3.25.4

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Deferred tax assets:
Net operating loss carryforwards	$ 3.2	$ 6.1
Tax credit carryforwards	7.6	2.1
Pension and deferred compensation	43.9	28.9
Other	17.0	17.9
Capitalized R&D expenses	32.3	30.1
Leases	26.3	21.5
Valuation allowance	(16.2)	(12.8)
Total deferred tax assets	114.1	93.8
Deferred tax liabilities:
Property, plant, and equipment	64.7	60.9
Tax on undistributed earnings of subsidiaries	2.3	0.4
Leases	25.7	22.0
Other	6.0	5.0
Total deferred tax liabilities	98.7	88.3
Net deferred tax asset	$ 15.4	$ 5.5

Amount of deferred tax liability attributable to taxable temporary differences.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

WEST PHARMACEUTICAL SERVICES INC 10-K